NRx Pharmaceuticals subsidiary initiates ONE-D depression treatment

HOPE Therapeutics, an interventional psychiatry network owned by NRx Pharmaceuticals (NRXP), announced initiation of patient care with for treatment-resistant depression with the Ampa one day, ONE-D, protocol. HOPE is the first to deploy the Ampa technology in Florida and one of the first deployments nationwide. The Ampa device differs from other Transcranial Magnetic Stimulation, TMS, treatments in that the peer-reviewed literature has reported a high rate of success in nonrandomized trials when a single day of TMS treatment is combined with physician-prescribed D-cycloserine and lisdexamfetamine. D-cycloserine was previously reported to substantially enhance the effectiveness of TMS in reducing depression and suicidality by more than two-fold in a placebo-controlled trial using a traditional TMS protocol. Additional supportive findings documenting the effect of D-cycloserine in enhancing the effect of TMS were recently published by a team of researchers led by Prof. Joshua Brown at Harvard’s McLean hospital.3 Dr. Brown additionally serves as the President of the Clinical TMS Society.